CCM/Market Reports-/Benchmarking on Paracetamol Production in China - 2nd edition

¡¡

(home)
CCM
consultancy
Market reports
Trade Analysis
newsletters & Information
conferences & events
coming report
ValoTracer
about us
careers 
contact
Always Primary Findings
Online Payment
samples
 

click here for sample pages

 

CCM>Market Reports>

 

No. 0005P027 Benchmarking on Paracetamol Production in China - 2nd edition  - Edition(2)

 

 

About This Report:

 

Report edition:  2008 edition(2)
Language version: English
Document type: PDF File,(*.pdf)
For ready report --    
  Finished in: Nov 2008 ,edition(2)
  Total pages: 116
  Delivery: Delivery within 1-1 work days by email
  Price/copy: - USD12000.00 for single user
    -USD26400.00 for corporate license/site license
For update report --  
  Delivery time: Delivery within 30-50 work days by email
  Price/copy: - USD15000.00 for single user PDF
    - USD37500.00 for corporate license/site license

 

* The corporate license/site license is only for the sole and confidential use within the subscriber company and its affiliates in which the subscriber company owns, directly or indirectly, a fifty percent or greater, financial interest.

 

Report Edition List:

 

Version Finished in Availability Language   Pages   Delivery Price/Copy (For single user)
update report - update on request English - within 30-50 work days by email USD15000.00
2008,edition(2) Nov,2008 available English 116 within 1-1 work days by email USD12000.00
2006,edition(1) June,2006 available English 93 within 1-1 work days by email USD12000.00

 

 

Description:

 

The consumption of paracetamol, which takes the most important position among NSAIDs, has kept growing worldwide, which promotes the production of PAP, the key raw material of paracetamol.

As one of main paracetamol manufacturers in the world, China's paracetamol export has constituted 30%-40% of the total paracetamol consumed in the world. On the other hand, process of PAP and paracetamol in China is improving, largely attributable to the governmental environmental protection policy.

However, China’s PAP manufacturers’ profit has been further squeezed by the growing investment in environmental protection and the global economic depression in 2008.

To further penetrate into the industry, especially the production process, CCM has produced a report of Benchmarking on PAP and Paracetamol Production in China, which will provide you with the answers to the following questions:

 What are the developing status and trends of the production processes of PAP and paracetamol in China?
 What are the production costs of these process by theoretical model?
 What are the actual production cost and total profit of benchmark enterprises of PAP and paracetamol in this report in China?
 How are the total profit comparison between benchmark enterprises of PAP and paracetamol?
What are the financial analysis of benchmark enterprises in 2007?
 What are the prospective technologies of PAP production in China till 2015?

 

Main Content:

 

No. Content
Page
Executive Summary
4
Introduction and methodologies
8
I Review of PAP & paracetamol industry
10
I-1 Brief introduction to paracetamol industry in China
10
I-2 Brief introduction to PAP industry in China
13
II Brief introduction to various technologies of PAP and paracetamol
16
II-1 Introduction to processes for PAP production
16
II-1.1 Industralized technologies of PAP in China
17
- Iron reduction of p-nitrophenol
17
- Catalytic hydrogenation of p-nitrophenol
18
- Catalytic hydrogenation of nitrobenzene
20
II-1.2 Technologies under research
21
- Electrolytic reduction of nitrobenzene
21
- Other findings
25
II-1.3 Comparison among the above four technologies
26
II-2 Introduction to processes for paracetamol production
27
II-2.1 One-step method
27
II-2.2 Two-step method
28
III Detailed introduction to most popular methods of PAP and paracetamol
30
III-1 Technology for PAP
30
III-1.1 Description of production process and theoretical model of raw materials by iron reduction technology
30
III-1.2 Description of production process and theoretical model of raw materials by nitrobenzene catalytic hydrogenation technology
33
III-2 Technology for paracetamol
37
III-2.1 Brief description of production process
37
III-2.2 Flow chart of paracetamol production
38
III-2.3 Theoretical model of raw materials
38
IV Estimation on cost and profit of PAP and paracetamol
40
IV-1 In PAP enterprises
40
IV-1.1 Jiangsu Zhongming (adopting PNCB technology)
40
- Basic situation in Jiangsu Zhongming
40
- Financial analysis of Jiangsu Zhongming in 2007
42
- Estimation on raw material cost
47
- Estimation on manufacturing cost
47
- Estimation on management cost
49
- Estimation on total production cost
49
- Estimation on profit
50
IV-1.2 Liaoning Tianbao (adopting PNCB technology)
52
- Basic situation in Liaoning Tianbao
52
- Financial analysis of Liaoning Tianbao in 2007
55
- Estimation on raw material cost
60
- Estimation on manufacturing cost
60
- Estimation on management cost
61
- Estimation on profit
61
IV-1.3 Liaoning Jinhua(adopting NB technology)
62
- Basic situation in Huludao Jinhu
62
- Estimation on raw material cost
63
- Estimation on manufacturing cost
64
- Estimation on management cost
64
- Estimation on profit
65
IV-1.4 Comparison among above three manufacturers
66
IV-2 In paracetamol enterprises
69
IV-2.1 Hebei Jiheng
69
- Basic situation in Hebei Jiheng
69
- Actual flowchart in Hebei Jiheng
70
- Financial analysis of Hebei Jiheng in 2007
72
- Estimation on raw material cost
77
- Estimation on manufacturing cost
78
- Estimation on management cost
79
- Estimation on total production cost
80
- Estimation on profit
80
IV-2.2 Lu'an Pharm
82
- Basic situation in Lu'an Pharm
82
- Financial analysis of Lu'an Pharm in 2007
83
- Estimation on raw material cost
83
- Estimation on manufacturing cost
89
- Estimation on management cost
89
- Estimation on total production cost
90
- Estimation on profit
91
IV-2.3 Comparison between Hebei Jiheng and Lu'an Pharm in profit
93
V Forecast on PAP & paracetamol industry in China
95
V-1 Forecast on market
95
V-2 Forecast on technology
95
V-3 Competitive power of Chinese paracetamol
97
VI Site visit reports
101

LIST OF TABLES
Table 1  Production situation of Chinese PAP producers, Nov-2008
Table 2  RMB/USD exchange rates, 1994-2008
Table I-1-1  Output of NSAIDs in China in 2007
Table I-1-2  Output, export, import and domestic consumption of paracetamol in China, 1998~2007
Table I-1-3  Average export price of Chinese paracetamol in 2007 and Jan-Aug. 2008
Table I-2-1  Export of Chinese PAP, 2000~2007
Table II-1-1  Major technologies of PAP production in China, 2008
Table II-1-2  Technologies adopted by overseas PAP producers
Table II-1-3  Production situation of Chinese PAP producers, Oct- 2008
Table II-1.2-1  Main patents on catalytic hydrogenation of nitrobenzene, 2004-2008
Table II-1.3 -1  Comparison among different technologies, Oct- 2008
Table II-2.3-1  Key researchers on paracetamol in China
Table III-1.1-1  Theoretical consumption of raw material of PAP in China, Oct- 2008
Table III-1.2-1  Theoretical consumption of raw material of PAP in China, Oct-2008
Table III-2.3-1  Theoretical estimation on raw material costs of paracetamol
Table IV-1.1-1  Main equipment in Jiangsu Zhongming
Table IV-1.1-2  General situation of Jiangsu Zhongming, Oct-2008
Table IV-1.1-3  Balance sheet of Jiangsu Zhongming in 2007
Table IV-1.1-4  Income statement of Jiangsu Zhongming in 2007
Table IV-1.1-5  Cash flow statement of Jiangsu Zhongming in 2007
Table IV-1.1-6  Financial analysis of Jiangsu Zhongming in 2007
Table IV-1.1-7  Raw material costs of PAP in Jiangsu Zhongming in Oct- 2008
Table IV-1.1-8  Estimation on manufacturing costs of PAP production in Jiangsu Zhongming, Oct-2008
Table IV-1.1-9  Estimation on management cost of Jiangsu Zhongming in Oct- 2008
Table IV-1.1-10  Estimation on total production costs in Jiangsu Zhongming, Oct-2008
Table IV-1.1-11  Tax ratio in China
Table IV-1.1-12  Estimation on profit of Jiangsu Zhongming, Oct-2008
Table IV-1.2-1  List of main sets of equipment in Liaoning Tianbao, Oct-2008
Table IV-1.2-2  General situation of Liaoning Tianbao
Table IV-1.2-3  Balance sheet of Liaoning Tianbao in 2007
Table IV-1.2-4  Income statement of Liaoning Tianbao in 2007
Table IV-1.2-5  Cash flow statement of Liaoning Tianbao in 2007
Table IV-1.2-6  Financial analysis of Liaoning Tianbao in 2007
Table IV-1.2-7  Raw material costs of PAP in Liaoning Tianbao in Oct-2008
Table IV-1.2-8  Estimation on manufacturing costs of PAP production in Liaoning Tianbao, Oct-2008
Table IV-1.2-9  Estimation on management cost of Jiangsu Zhongming, Oct-2008
Table IV-1.2-10  Estimation on profit of Liaoning Tianbao, Oct-2008
Table IV-1.3-1  Estimation on raw material cost of PAP in Liaoning Jinhua, Oct-2008
Table IV-1.3-2  Estimation on manufacturing costs of PAP production in Liaoning Jinhua, Oct-2008
Table IV-1.3-3  Estimation on management cost of Liaoning Jinhua, Oct-2008
Table IV-1.3-4  Estimation on profit of Liaoning Jinhua
Table IV-1.4-1  Comparison of cost between Jiangsu Zhongming and Liaoning Tianbao, Oct-2008
Table IV-1.4-2  Comparison of income and profit between Jiangsu Zhongming and Liaoning Tianbao, Oct-2008
Table IV-1.4-3  Comparison of cost and profit between Jiangsu Zhongming, Liaoning Tianbao and Liaoning Jinhua, Oct-2008
Table IV-2.1-1  Balance sheet of Hebei Jiheng in 2007
Table IV-2.1-2  Income statement of Hebei Jiheng in 2007
Table IV-2.1-3  Cash flow statement of Hebei Jiheng in 2007
Table IV-2.1-4  Financial analysis of Hebei Jiheng in 2007
Table IV-2.1-5  Estimation on raw material costs of paracetamol in Hebei Jiheng
Table IV-2.1-6  Manufacturing costs of paracetamol production in Hebei Jiheng
Table IV-2.1-7  Estimation on management cost of Hebei Jiheng
Table IV-2.1-8  Estimation of total production cost in Hebei Jiheng
Table IV-2.1-9  The profit estimation of paracetamol in Hebei Jiheng
Table IV-2.2-1  Balance sheet of Lu’an Pharm in 2007
Table IV-2.2-2  Income statement of Lu’an Pharm in 2007
Table IV-2.2-3  Cash flow statement of Lu’an Pharm in 2007
Table IV-2.2-4  Financial analysis of Lu’an Pharm in 2007
Table IV-2.2-5  Estimation on raw material costs of paracetamol in Lu’an Pharm
Table IV-2.2-6  Manufacturing costs of paracetamol production in Lu’an Pharm
Table IV-2.2-7  Estimation on management cost of Lu’an Pharm
Table IV-2.2-8  Estimation of total production cost in Lu’an Pharm
Table IV-2.2-9  The profit estimation of paracetamol in Lu’an Pharm
Table IV-2.3-1  Comparison between Hebei Jiheng and Lu’an Pharm in Oct 2008
Table V-2-1  Estimation on future technology structure of PAP in China, tonnes, 2008-2015
Table V-3-1  SWOT analysis of the top five paracetamol manufacturers in China
Table VI-1-1  List of main equipment of PAP production in Jiangsu Zhongming
Table VI-1-2  PAP specification in Jiangsu Zhongming
Table VI-2-1  List of main equipments in Liaoning Tianbao
Table VI-2-2  PAP specification in Liaoning Tianbao
Table VI-3-1  Equipments affiliated to 3,000 t/a PAP production line in Liaoning Tiancheng

LIST OF FIGURES
Figure1  Forecast on technology structure of PAP in China, 2008-2015
Figure I-1-1  Market share of main NSAIDs in China in 2007
Figure I-1-2  Export situation to different destinations of Chinese paracetamol, 2003~2007
Figure 1-1-3  Average export price of Chinese paracetamol, 1999~2007
Figure I-2-1  Output of PAP in China, 1998~2007
Figure I-2-2  Export volume and price of PAP produced by different process in China, 2000~2007
Figure I-2-3  Consumption structure of PAP in China, 2007
Figure V-2-1  Forecast on technology structure of PAP in China, 2008-2015, by output volume
Figure V-2-2  Forecast on technology structure of PAP in China, 2008-2015, by output share

Part of Report: click here for sample pages

Executive Summary

(Note: The following summary is based on the situation in 2008 and maybe different to what it is nowadays. Please be noted.)



- Technologies of Chinese enterprises

In the past decade, China’s paracetamol and PAP industry has boomed quickly, and both of their output grows with CAGR of more than xx%. Chinese manufacturers mainly adopt iron reduction method and catalytic hydrogenation of p-nitrophenol to produce PAP, among which iron reduction method accounts for xx% of the total capacity currently.

XXX Co., Ltd. is the largest PAP producer in China, with PAP capacity of xxxxt/a in 2008. XXX Co., Ltd. is the only Chinese PAP producer that adopts catalytic hydrogenation of p-nitrophenol, and its capacity of PAP is xxxxt/a in 2008.

Though overseas PAP manufacturers mostly adopt more advanced technologies including catalytic hydrogenation of nitrobenzene and electrolytic reduction of nitrobenzene, these technologies are still under research now in China.

- Cost and profit of Chinese enterprises

Production cost of PAP of Chinese enterprises ranges from USDxxxx/t to USDxxxx/t in November 2008. It is noted that cost of raw materials constitutes more than XX% of the total production cost. It even approaches xx% in XXX Chemical Plant and xx% in XXX Co., Ltd., two companies CCM has visited and investigated.

CCM estimates that the profit level of Chinese PAP manufacturers is actually very low. Profit of PAP in XXX reaches USDxxxx/t, which it is only USDxxxx/t in XXX in November 2008. During the corresponding period, their quoted price of PAP is USDxxxx/t and USDxxxx/t respectively, whereas, Chinese paracetamol producers disclosed that they were often able to purchase domestic PAP at a price of about USDxxxx/t.

Paracetamol production is mature in China and the production cost among different manufacturers is nearly the same. To those armed with complete equipment such as XXX, though they have heavy burden on paying for interest and amortization and the production cost is high, they can gain more profit for higher price and larger production scale.

- Forecast on PAP and paracetamol production

Motivated by demands from both domestic and international markets, Chinese paracetamol will keep on developing relatively rapidly in the coming several years. It is estimated by CCM that the annual growth rate of paracetamol output will amount to nearly xx% in the coming five years.

......

(The rest content of this report is omitted.)

Character of CCM' Report:

This multi-client report provides a comprehensive study on the researched subject in China, from aspects of production, technology, import & export, consumption & end uses, etc.

>>
 All the producers in China, either active or idled or potential, have been sourced and contacted. Their situation has been verified and compiled as in the appendix.
>>
 The competitiveness of Chinese production has been discussed in order to uncover the mystery of ever-increasing capability of Chinese manufacturing.
>>
 The import & export analysis for the situation in the recent three years has been conducted.
>>
 The consumption pattern of the researched subject has been carried out in order to breakdown the end uses into different segments. The major end users under each major end use segments have been identified.
>>
 The scientific methodology has been employed to conduct the quantitative forecast on this subject in the future 5-10 years.

The aim of this report is to provide powerful assistance to the strategy group and the management team in making correct decision as how to penetrate the ever-increasing China market and how to catch the maximum commercial opportunities. The report is formulated independently by CCM’s professional market researchers, based on the first-hand and primary data which are analyzed by scientific methodology, confirmed with both manufacturers/end users/traders and legal authorities, and presented in a logic way.

Remark:

If you are not satisfied with the above main content, or if you would like to add additional requirements to the mentioned subject, or if you could not find your interested item(s) via the search engine, you are advised to go to Single-Client Services and Advisor, or Contact Us.